Ratings by Credit Suisse (Brad Canino)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 4/7/2021 | Affimed Therapeutics | AFMD | Maintain | Outperform (N/A) |
|
Details | ||
| 3/31/2021 | Deciphera | DCPH | New Coverage | Outperform (N/A) |
40.40 (14.71) |
-63.59% | Details | |
| 3/31/2021 | Blueprint Medicines | BPMC | New Coverage | Neutral (N/A) |
92.01 (93.08) |
1.16% | Details | |
| 3/31/2021 | Exelixis | EXEL | New Coverage | Outperform (N/A) |
22.08 (23.71) |
7.38% | Details | |
| 3/31/2021 | Epizyme | EPZM | New Coverage | Outperform (N/A) |
7.45 (1.47) |
-80.27% | Details | |
| 3/31/2021 | Zymeworks | ZYME | New Coverage | Outperform (N/A) |
29.83 (8.60) |
-71.17% | Details | |
| 3/31/2021 | Affimed Therapeutics | AFMD | New Coverage | Outperform (N/A) |
7.32 (5.00) |
-31.69% | Details | |
| 3/31/2021 | Mersana | MRSN | New Coverage | Neutral (N/A) |
15.97 (2.88) |
-81.97% | Details | |
| 3/31/2021 | Seagen | SGEN | New Coverage | Neutral (N/A) |
139.93 (228.74) |
63.47% | Details |
